Guggenheim Securities · 1 day ago
Equity Research Associate – Biotechnology
New York, United States
Full-time
Onsite
New Grad, Entry Level
$140K/yr - $165K/yrGuggenheim Securities is seeking an exceptional candidate to join as a sell-side Equity Research Associate to help cover the Biotechnology sector. The role involves conducting fundamental analysis and investment research, specifically focusing on public and private Biotechnology companies, and providing support to the research team in making stock recommendations to institutional investors.
Financial Services
Responsibilities
Provide support to the Senior Analyst through fundamental analysis and investment research in equity markets with an emphasis on original, bottom-up research in the Biotechnology sector
Analyze individual Biotechnology companies to build and update fully integrated financial and valuation models
Write comprehensive research reports and present findings; draft reports/notes on relevant investment themes, events, and breaking news
Conduct primary research through industry sources including, but not limited to, financial analysis, due diligence clinical data and industry trends, company management and strategies
Organize physician calls for investors and investor events
Update analyst marketing handout regularly
Interact with Firm’s institutional sales force and investor clients
Respond to client and internal inquiries regarding research findings and directives
Qualification
Required
Exceptional academic pedigree, including a higher degree in a life science field (PhD) or MD
Ability to search, understand, and interpret scientific and medical publications and presentations
Preferred
Experience in PK/ PD plus
Experience with R or other modeling software packages are a plus
Prior experience at a bio-pharmaceutical company is preferred
Exceptional analytical, verbal, and written communication skills
Company
Guggenheim Securities
Guggenheim Securities is the investment banking and capital markets business of Guggenheim Partners. It is a sub-organization of Guggenheim Partners.
1001-5000 employees
H1B Sponsorship
Guggenheim Securities has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (13)
2024 (10)
2023 (10)
2022 (13)
2021 (18)
2020 (13)
Funding
Current Stage
Late StageLeadership Team
Mark Van Lith
Chief Executive Officer
Recent News
2026-01-07
2025-12-17
Company data provided by crunchbase